“TECNALIA integrates NGS technologies to tailor prevention, diagnosis and treatments for hereditary cancer and somatic tumours”
Leading facility on genetic oncology
TECNALIA’s Genetics Laboratory has reinforced its position as a leading facility on genetic oncology, incorporating next-generation sequencing (NGS) technologies that will make it possible to analyse oncological pathology with advanced molecular resolution.
These capabilities will make it possible to identify a person's hereditary predisposition to cancer and carry out the genomic profiling of somatic tumours, two areas that are essential for precision medicine.
Diagnosis of hereditary tumour syndromes
A significant proportion of tumours (around 10%) have a hereditary component.
- To carry out its research, TECNALIA has NGS panels targeting the main tumour predisposition syndromes, including hereditary breast and ovarian cancer (HBOC), Lynch syndrome, and other monogenic disorders with a high clinical impact.
- These panels cover key genes such as BRCA1, BRCA2, MLH1, MSH2, TP53, PTEN, among others, making it possible to assess individual risk, familial transmission and the genetic stratification of patients and their relatives. Its design is flexible and adaptable, incorporating new genes and variants as scientific evidence evolves.
Genetic studies of somatic tumours
TECNALIA provides pan-cancer and tumour-specific panels that make it possible to carry out a comprehensive molecular characterisation of tumours, with the aim of improving diagnoses, optimising the selection of targeted therapies and increasing the efficacy of anti-tumour treatments.
- These analyses can identify SNVs, indels, CNVs, gene fusions, TMB and MSI, and carry out HRD testing, providing critical information for identifying predictive biomarkers, stratification in clinical trials (EECC), assessing therapeutic response and selecting targeted therapies.
- The availability of extensive, specialised panels allows studies to be tailored to the specific biology of each tumour.
These services are aimed at medical oncologists, clinical geneticists, molecular pathologists, genetic counselling teams, hospital diagnostic services, clinical trial units, and translational research groups that require high-precision genomic analyses for making clinical decisions and developing new drugs.